Other therapy areas take a back seat as the pharma industry continues to focus on cancer-focused licensing deals.
When the World Congress on Lung Cancer kicks off in Toronto later this month all eyes will be on Roche’s Impower-133 study.
Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.
The companies have taken a different label-expansion approach to rivals Johnson & Johnson and Bayer, but all are hoping for a win in cancer patients.
Bristol-Myers Squibb should soon unveil data showing whether Opdivo’s liver cancer use could be broadened from second to first line, while Amicus investors look for a…
Licensing deal activity holds up in first half of 2018 as biopharma continues to stay away from takeovers.
After falling short in a label-extension trial Johnson & Johnson still sees a path forward for its blood thinner in preventing venous thromboembolism.
The Commander HF trial closes the door on a very sick heart failure population, leaving Johnson & Johnson and Bayer's label-expansion strategy looking shaky.
Johnson & Johnson and Bayer’s label-expansion strategy takes a hit, handing the advantage back to Bristol-Myers Squibb and Pfizer's Eliquis.